Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Lancet Infect Dis. 2023 Jul;23(7):847-855. doi: 10.1016/S1473-3099(23)00067-1. Epub 2023 Mar 23.
Lancet Infect Dis. 2023.
PMID: 36966799
Clinical Trial.
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, Lu Q, Kusmiati T, Balanag VM, Lee SL, Ruslami R, Pokharkar Y, Djaharuddin I, Sugiri JJR, Veto RS, Sekaggya-Wiltshire C, Avihingsanon A, Sarin R, Papineni P, Nunn AJ, Crook AM; TRUNCATE-TB Trial Team.
Paton NI, et al. Among authors: dalay vb.
N Engl J Med. 2023 Mar 9;388(10):873-887. doi: 10.1056/NEJMoa2212537. Epub 2023 Feb 20.
N Engl J Med. 2023.
PMID: 36808186
Clinical Trial.
Item in Clipboard
Patient-cost survey for tuberculosis in the context of patient-pathway modelling.
Tomeny EM, Mendoza VL, Marcelo DB, Barrameda AJD, Langley I, Abong JM, Dalay VB, Yu CY, Squire SB.
Tomeny EM, et al. Among authors: dalay vb.
Int J Tuberc Lung Dis. 2020 Apr 1;24(4):420-427. doi: 10.5588/ijtld.19.0206.
Int J Tuberc Lung Dis. 2020.
PMID: 32317067
Item in Clipboard
Cite
Cite